Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Multiple sclerosis and related disorders·2026
Same author

Dim Flicker: An Endogenous Visual Percept and Its Disease Associations.

Journal of clinical medicine·2026
Same author

Prospective clinical evaluation of automatic lesion assessment in patients with multiple sclerosis.

Neuroradiology·2025
Same author

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Brain : a journal of neurology·2025
Same author

Letter in reply.

Journal of the neurological sciences·2025
Same author

Blood-brain barrier permeability in relation to disease severity and timing of multiple sclerosis diagnosis in optic neuritis.

Multiple sclerosis journal - experimental, translational and clinical·2025

Related Experiment Video

Updated: Jul 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K

Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis.

Mia Topsøe Mailand1, Jette Lautrup Frederiksen2

  • 1University of Copenhagen, Rigshospitalet Glostrup, Glostrup, Denmark. mia.mailand@gmail.com.

Molecular Diagnosis & Therapy
|March 13, 2020
PubMed
Summary

Intrathecal immunoglobulin M (IgM) may indicate a worse prognosis in multiple sclerosis (MS) patients, suggesting a higher risk of disease progression. Further research is needed to confirm its role as a prognostic marker.

More Related Videos

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.5K
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

10.5K

Related Experiment Videos

Last Updated: Jul 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.5K
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

10.5K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Identifying prognostic markers for multiple sclerosis (MS) is crucial for patient management.
  • Intrathecal immunoglobulin M (IgM) production has been linked to a more severe MS disease course.

Purpose of the Study:

  • To review evidence on intrathecal IgM as a prognostic marker for clinically isolated syndrome (CIS) conversion to clinically definite MS (CDMS).
  • To assess intrathecal IgM's role in predicting MS prognosis and treatment response.

Main Methods:

  • A systematic literature search of the PubMed database was conducted.
  • 719 articles were identified, and 29 relevant studies were included after applying inclusion/exclusion criteria.

Main Results:

  • Current evidence suggests intrathecal IgM is a negative prognostic marker.
  • It identifies patients with CIS at higher risk of converting to CDMS and RRMS patients with a more aggressive disease course.
  • Some studies reported conflicting results, necessitating further investigation.

Conclusions:

  • Intrathecal IgM shows potential as a negative prognostic marker in MS.
  • More research is required to accurately estimate its impact on MS disease course and treatment response.